Similarly, upregulation of PD-L1 was noted in patient cohorts with myelodysplastic syndromes (MDS) harboring TP53 mutations and secondary AML (sAML) (Sallman et al., 2020). This evidence concerns the gene TP53 and myelodysplastic syndrome.